K. Podratz, P. O'brien, G. Malkasian
Jul 1, 1985
Citations
1
Influential Citations
117
Citations
Quality indicators
Journal
Obstetrics & Gynecology
Abstract
Progestational agents induced an objective response in 11.2% of 155 patients with advanced primary or recurrent endometrial carcinoma. Response rates decreased with decreasing tumor differentiation from 40% with Broders grade 1 lesions to 17.5, 2.4, and 0%, respectively, with grades 2, 3, and 4. 17α-Hydroxyprogesterone caproate (Delalutin), 6,17α-dimethyl-6-dehydroprogesterone (Colprone), and 6- methyl-6-dehydroprogesterone acetate (Megace) were the progestogens used; there was no significant advantage for any one agent. Overall, survival after initiation of hormone therapy was 40% at one year, 19% at two years, and 8% at five years. Survival was highly dependent on the degree of tissue differentiation (P<.001) and was influenced significantly by the estimated tumor volume at the start of therapy (P<.01) and by the time interval from primary treatment to the beginning of hormone therapy (P<.01).